<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303562</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 9571</org_study_id>
    <nct_id>NCT01303562</nct_id>
  </id_info>
  <brief_title>Clinical Assessment of Barley and Oat Phytochemicals</brief_title>
  <official_title>Clinical Assessment of Barley and Oat Phytochemicals: Acute Bioavailability, Pharmacokinetics, and Bioactivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kellogg Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts University</source>
  <brief_summary>
    <textblock>
      The goal of this placebo-controlled, 3-way crossover study is to determine the acute (24-h)&#xD;
      bioavailability and pharmacokinetics of the major phytochemicals found whole barley and oats,&#xD;
      as well as their effects on selected measures of antioxidation, inflammation, insulin&#xD;
      sensitivity/glucose regulation, and vascular remodeling following challenge by an oral&#xD;
      glucose tolerance test (OGTT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of phytochemicals and their in vivo metabolites in blood</measure>
    <time_frame>24 hours</time_frame>
    <description>Levels of phytochemicals and their in vivo metabolites in blood, urine, and feces following the consumption of whole grains delivered in a baked muffin</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo muffin made with no whole grains</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Test muffin made with whole oats</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Test muffin made with whole barley</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Whole grain oats and barley</intervention_name>
    <description>One time dose of 48 g whole grain flour in 2 small muffins (24 g flour per muffin) per intervention</description>
    <arm_group_label>Placebo muffin made with no whole grains</arm_group_label>
    <arm_group_label>Test muffin made with whole barley</arm_group_label>
    <arm_group_label>Test muffin made with whole oats</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and postmenopausal women&#xD;
&#xD;
          -  BMI 27-35.9 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cigarette smoking and/or nicotine replacement use&#xD;
&#xD;
          -  Individuals taking estrogen&#xD;
&#xD;
          -  Use of cholesterol-lowering medications&#xD;
&#xD;
          -  Use of blood pressure-lowering medications&#xD;
&#xD;
          -  Regular use of any stomach acid-lowering medications or laxatives (including fiber&#xD;
             supplements)&#xD;
&#xD;
          -  Cardiovascular (heart) disease&#xD;
&#xD;
          -  Gastrointestinal disease&#xD;
&#xD;
          -  Kidney disease&#xD;
&#xD;
          -  Endocrine disease: including diabetes, untreated thyroid disease&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Active treatment for any type of cancer, except basal cell carcinoma, within 1 year&#xD;
             prior to study admission&#xD;
&#xD;
          -  Systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 95 mmHg&#xD;
&#xD;
          -  Regular use of oral steroids&#xD;
&#xD;
          -  Regular daily intake of â‰¥ 2 alcoholic drinks&#xD;
&#xD;
          -  Infrequent or excessive number of regular bowel movements&#xD;
&#xD;
          -  Illicit drug use&#xD;
&#xD;
          -  Vegetarians&#xD;
&#xD;
          -  No fish oil supplements (including cod liver oil) for one month prior to study&#xD;
             admission&#xD;
&#xD;
          -  No dietary supplements, including those containing any vitamins, minerals, herbs,&#xD;
             plant concentrates (including garlic, gingko, St. John's wort) or homeopathic&#xD;
             remedies, for one month prior to study admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey B Blumberg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts Clinical and Translational Research Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>November 16, 2010</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <last_update_submitted>May 23, 2013</last_update_submitted>
  <last_update_submitted_qc>May 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oat</keyword>
  <keyword>barley</keyword>
  <keyword>whole grain</keyword>
  <keyword>bioavailability</keyword>
  <keyword>phytochemical</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

